OpenEvidence, an AI healthcare startup, has raised a new $250 million funding round, lifting its valuation to approximately $12 billion. The investment underscores continued investor interest in vertical AI applications within healthcare, particularly tools designed to support clinical decision-making.
The company operates an AI-powered medical search and clinical support platform that delivers evidence-based insights to physicians. OpenEvidence has reported rapid growth in usage, processing millions of clinical queries each month, with broad adoption among U.S. doctors. Revenue is primarily generated through advertising, with additional monetization tied to its expanding product offerings.
As OpenEvidence scales its platform and commercial footprint, the company continues to navigate safety, accuracy, and regulatory considerations common to AI systems used in clinical environments.
#Investor Takeaway
OpenEvidence’s increased valuation reflects sustained investor confidence in healthcare-focused AI platforms and their potential to become core tools in medical practice.
#Market Impact
The funding round reinforces positive sentiment toward the healthcare AI sector, highlighting strong demand for specialized AI solutions with clear revenue models and professional adoption.
#What’s Next
Investors and industry observers will be watching for further updates on product expansion, revenue growth, and how the company addresses regulatory and clinical safety requirements as it scales.